For the year ending 2025-12-31, WST had $306,700K increase in cash & cash equivalents over the period. $468,900K in free cash flow.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net income | 493,700 | 492,700 | 593,400 | 585,900 |
| Depreciation | 168,600 | 151,800 | 133,700 | 116,900 |
| Amortization | 2,800 | 3,600 | 3,600 | 3,700 |
| Stock-based compensation | 23,800 | 18,700 | 23,300 | 23,700 |
| Non-cash restructuring charges | 5,400 | 0 | 0 | 15,300 |
| Pension settlement charges | 0 | 0 | -100 | -52,200 |
| Contingent consideration payments in excess of acquisition-date liability | - | - | - | 2,000 |
| Loss on disposal of plant | 0 | 0 | -11,600 | -2,700 |
| Asset impairments | 11,700 | 7,300 | 9,600 | - |
| Deferred income taxes | -13,700 | -3,500 | 37,500 | -30,800 |
| Pension and other retirement plans, net | 600 | -2,000 | -2,600 | -14,000 |
| Equity in undistributed earnings of affiliates, net of dividends | 10,500 | 13,400 | 14,300 | 18,100 |
| Other, net | 7,400 | 4,700 | -1,000 | - |
| Decrease (increase) in accounts receivable | -6,900 | 58,800 | -4,000 | 35,600 |
| (increase) decrease in inventories | 62,800 | -42,000 | 13,500 | 49,800 |
| Decrease (increase) in other current assets | -9,700 | 5,800 | 21,300 | -18,500 |
| Increase in accounts payable | 17,900 | 2,900 | 4,400 | -2,800 |
| Changes in other assets and liabilities | -108,100 | -22,600 | -6,000 | -58,200 |
| Net cash provided by operating activities | 754,800 | 653,400 | 776,500 | 724,000 |
| Capital expenditures | 285,900 | 377,000 | 362,000 | 284,600 |
| Acquisition of business | - | - | 0 | 0 |
| Other, net | 0 | 1,700 | 6,700 | 3,600 |
| Net cash used in investing activities | -285,900 | -378,700 | -368,700 | -288,200 |
| Borrowings of long-term debt | 0 | 164,700 | - | - |
| Repayments of long-term debt | 0 | 169,000 | - | 1,200 |
| Debt issuance cost | - | 0 | 0 | 44,300 |
| Repayments of long-term debt | - | - | 2,300 | - |
| Principal repayments on finance leases | 1,100 | 23,300 | - | - |
| Dividend payments | 61,200 | 59,100 | 57,000 | 54,100 |
| Excise tax payments | 4,200 | 2,000 | - | - |
| Proceeds from stock-based compensation awards | 11,300 | 25,500 | 43,900 | 20,900 |
| Employee stock purchase plan contributions | 6,900 | 7,200 | 7,100 | 7,300 |
| Shares purchased under share repurchase programs | 134,000 | 560,900 | 438,300 | 202,800 |
| Shares repurchased for employee tax withholdings | 2,800 | 5,700 | 12,900 | 19,400 |
| Other, net | - | - | -100 | - |
| Net cash used in financing activities | -185,100 | -622,600 | -459,600 | -293,600 |
| Effect of exchange rates on cash | 22,900 | -21,400 | 11,400 | -10,500 |
| Net increase (decrease) in cash and cash equivalents | 306,700 | -369,300 | -40,400 | 131,700 |
| Cash and cash equivalents at beginning of period | 484,600 | 853,900 | 894,300 | 762,600 |
| Cash and cash equivalents at end of period | 791,300 | 484,600 | 853,900 | 894,300 |
WEST PHARMACEUTICAL SERVICES INC (WST)
WEST PHARMACEUTICAL SERVICES INC (WST)